Mankind Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	-	3,917	4,074	3,820	3,048	3,025
Short-Term Investments	-	2,787	3,980	7,464	1,413	1,023
Trading Asset Securities	-	15,373	16,908	22,581	10,755	8,745
Cash & Short-Term Investments	22,077	22,077	24,962	33,865	15,216	12,793
Cash Growth	-11.56%	-11.56%	-26.29%	122.56%	18.94%	-36.18%
Accounts Receivable	-	17,295	15,383	8,483	5,764	3,882
Other Receivables	-	492.3	363	437.1	321.02	347.23
Receivables	-	17,831	15,786	8,949	6,102	4,241
Inventory	-	21,445	20,937	15,535	14,985	17,602
Prepaid Expenses	-	515	611.2	603.9	331.6	1,360
Other Current Assets	-	7,675	7,587	6,730	6,645	8,072
Total Current Assets	-	69,542	69,883	65,682	43,279	44,068
Property, Plant & Equipment	-	36,143	32,140	31,387	30,170	23,896
Long-Term Investments	-	4,517	4,848	3,111	3,578	2,404
Goodwill	-	64,926	64,926	200.2	200.23	204.42
Other Intangible Assets	-	96,411	101,236	16,630	17,584	18,742
Long-Term Deferred Tax Assets	-	3,247	1,079	803.9	297.77	392.86
Other Long-Term Assets	-	6,009	3,484	1,818	2,046	1,770
Total Assets	-	280,795	277,595	119,633	97,154	91,477
Accounts Payable	-	13,413	11,334	7,771	10,082	10,764
Accrued Expenses	-	8,521	7,812	5,487	1,710	2,598
Short-Term Debt	-	8,215	26,957	1,515	1,150	8,052
Current Portion of Long-Term Debt	-	25,616	2,611	196.9	244.68	242.47
Current Portion of Leases	-	357.7	143.9	34.2	25.57	20.57
Current Income Taxes Payable	-	109.1	180.8	83.8	462.56	150.9
Current Unearned Revenue	-	1,922	1,940	1,859	1,662	1,394
Other Current Liabilities	-	6,919	5,656	4,251	3,294	3,013
Total Current Liabilities	-	65,073	56,636	21,197	18,631	26,235
Long-Term Debt	-	28,212	55,262	248.7	231.47	491.94
Long-Term Leases	-	714.3	140.3	77.1	51.78	29.9
Long-Term Unearned Revenue	-	299.4	200	229.6	254.95	201.54
Pension & Post-Retirement Benefits	-	2,487	1,551	1,231	978.89	800.04
Long-Term Deferred Tax Liabilities	-	18,400	18,125	890.7	773.12	556.21
Total Liabilities	-	115,185	131,914	23,875	20,922	28,314
Common Stock	-	412.8	412.6	400.6	400.59	400.59
Additional Paid-In Capital	-	30,432	30,075	421.2	421.17	421.17
Retained Earnings	-	140,420	121,451	101,566	82,499	69,729
Comprehensive Income & Other	-	-8,261	-8,615	-8,757	-8,969	-8,999
Total Common Equity	163,003	163,003	143,324	93,631	74,352	61,552
Minority Interest	-	2,607	2,358	2,127	1,881	1,611
Shareholders' Equity	165,611	165,611	145,682	95,758	76,233	63,163
Total Liabilities & Equity	-	280,795	277,595	119,633	97,154	91,477
Total Debt	63,115	63,115	85,115	2,072	1,704	8,836
Net Cash (Debt)	-41,039	-41,039	-60,153	31,793	13,512	3,957
Net Cash Growth	-	-	-	135.29%	241.51%	-77.06%
Net Cash Per Share	-99.29	-99.29	-148.63	79.25	33.73	9.88
Filing Date Shares Outstanding	412.83	412.83	412.58	400.64	400.59	400.59
Total Common Shares Outstanding	412.83	412.83	412.58	400.59	400.59	400.59
Working Capital	-	4,470	13,247	44,485	24,647	17,834
Book Value Per Share	394.85	394.85	347.39	233.73	185.61	153.65
Tangible Book Value	1,666	1,666	-22,838	76,800	56,568	42,606
Tangible Book Value Per Share	4.04	4.04	-55.35	191.72	141.21	106.36
Land	-	3,808	3,801	3,530	3,528	2,435
Buildings	-	10,626	10,373	12,487	10,460	5,863
Machinery	-	26,296	24,513	21,504	17,352	13,921
Construction In Progress	-	6,548	3,061	2,071	4,932	6,699
Leasehold Improvements	-	136.7	101.9	88.8	88.74	64.47